Skip to Content
News|Coronavirus pandemic
COVID: New Omicron subvariant ‘appears to have growth advantage’
The UK Health security agency says early assessment does not find difference in vaccine effectiveness against symptomatic disease between Omicron subtypes.
People queue for their booster dose outside a coronavirus disease (COVID-19) vaccination centre in London [File: Hannah McKay/Reuters]
28 Jan 2022
The BA.2 subtype of the Omicron coronavirus variant appears to have a substantial growth advantage over the currently predominant BA.1 type, the United Kingdom’s Health Security Agency has said.
UKHSA said on Friday there was an increased growth rate of BA.2 compared with BA.1 in all regions of England where there were enough cases to compare them, and that “the apparent growth advantage is currently substantial”.
“We now know that BA.2 has an increased growth rate which can be seen in all regions in England,” said Dr Susan Hopkins, Chief Medical Advisor for the UKHSA.
The agency said there was no data on the severity of BA.2 compared with BA.1, but reiterated that a preliminary assessment did not find a difference in vaccine effectiveness against symptomatic disease between the two Omicron subtypes.
The rapid spread of BA.1 fuelled an Omicron wave which pushed daily infections to record highs in the UK in December, displacing the previously dominant Delta variant.
However, hospitalisations did not rise at the same rate, owing to population immunity through vaccination and previous infection, as well as Omicron’s lower severity.
The UKHSA said that a separate analysis showed that between November 24 and January 19, the majority of intensive care admissions from COVID-19 had Delta infections, even as Omicron was starting to dominate the number of cases.
It also found that a rise in cases of Omicron in care homes had not been associated with an increase in hospital admissions.
“Our findings suggest the current wave of Omicron infections is unlikely to lead to a major surge in severe disease in care home populations with high levels of vaccine coverage and/or natural immunity,” UKHSA said, noting that the findings were based on BA.1 due to limited numbers of BA.2 cases in the study.
Follow Al Jazeera English:
© 2022 Al Jazeera Media Network
You rely on Al Jazeera for truth and transparency
We understand that your online privacy is very important and consenting to our collection of some personal information takes great trust. We ask for this consent because it allows Al Jazeera to provide an experience that truly gives a voice to the voiceless. You have the option to decline the cookies we automatically place on your browser but allowing Al Jazeera and our trusted partners to use cookies or similar technologies helps us improve our content and offerings to you. You can change your privacy preferences at any time by selecting ‘Cookie preferences’ at the bottom of your screen.To learn more, please view our Cookie Policy.